Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;2(4):257-64.
doi: 10.1007/BF02698052.

Reprogramming somatic gene activity by fusion with pluripotent cells

Affiliations
Review

Reprogramming somatic gene activity by fusion with pluripotent cells

Jeong Tae Do et al. Stem Cell Rev. 2006.

Abstract

Fertilized eggs and early blastomeres, that have the potential to develop to fetuses when placed into a uterus, are totipotent. Those cells in the embryo, that can give rise to all cell types of an organism, but not to an organism itself, are pluripotent. Embryonic stem (ES), embryonic carcinoma (EC), and embryonic germ (EG) cells are powerful in vitro artifacts derived from different embryonic stages and are pluripotent. Totipotent and pluripotent cells have the potential to greatly benefit biological research and medicine. One powerful feature is that the genetic program of somatic cells can be converted into that of totipotent or pluripotent cells, as shown by nuclear transfer or cell fusion experiments. During reprogramming by cell fusion various features of pluripotent cells are acquired. These include the typical morphology of the respective pluripotent fusion partner, a specific epigenetic state, a specific gene profile, inactivation of tissue-specific genes expressed in the somatic fusion partner, and the developmental as well as differentiation potential of pluripotent cells. In this review, we will discuss what is known about the reprogramming process mediated by cell fusion and the potential use of fusion-induced reprogramming for therapeutic applications.

PubMed Disclaimer

Similar articles

Cited by

References

    1. EMBO Rep. 2002 Mar;3(3):224-9 - PubMed
    1. Nature. 2003 Oct 30;425(6961):968-73 - PubMed
    1. Blood. 2005 Jul 15;106(2):756-63 - PubMed
    1. EMBO J. 1997 Nov 3;16(21):6510-20 - PubMed
    1. Hum Mol Genet. 2004 Apr 1;13(7):727-39 - PubMed

LinkOut - more resources